Stay updated on Ipilimumab Nivolumab Radiation in HPV+ Oropharyngeal Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab Nivolumab Radiation in HPV+ Oropharyngeal Clinical Trial page.

Latest updates to the Ipilimumab Nivolumab Radiation in HPV+ Oropharyngeal Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page has been updated to reflect a new version number, changing from v2.15.0 to v2.15.2, and the phrasing regarding the last update has been clarified.SummaryDifference0.1%
- Check15 days agoChange DetectedThe webpage has been updated to reflect a new phase 2 study involving Ipilimumab and Nivolumab for treating HPV-positive oropharyngeal carcinoma, with a new estimated last update date of April 2025.SummaryDifference2%
- Check22 days agoChange DetectedThe webpage has undergone significant updates, including the addition of detailed clinical stages and types of HPV-mediated oropharyngeal carcinoma, as well as the inclusion of a quality-of-life assessment and a new registry identifier. However, extensive information regarding the study's objectives, treatment protocols, and inclusion/exclusion criteria has been removed.SummaryDifference53%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to Ipilimumab Nivolumab Radiation in HPV+ Oropharyngeal Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab Nivolumab Radiation in HPV+ Oropharyngeal Clinical Trial page.